ERBB2 and breast cancer: Although most studies failed to report an association between PTEN loss and prognosis in BC patients enrolled in clinical trials, emerging evidence suggests that lack or decrease in PTEN expression may be associated with worse outcomes in HR+/HER2 negative (HER2-) or HER2+ BC.